Investlytic Investlytic
Log in Free Account
English
🕒 Last update: loading…06/11/2026

Stock ResMed Inc. RMD

ResMed Inc. — Investlytic score 5/5 on the five criteria.

-
-
100/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 5/5 criteria met. Data as of 04/11/2026.

  • ✅ Price trend passed
  • ✅ Growth passed
  • ✅ Debt passed
  • ✅ P/E passed
  • ✅ Correction passed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 36.09%

Price change 2019 → 2020: 37.16%

Price change 2020 → 2021: 22.54%

Price change 2021 → 2022: -20.10%

Price change 2022 → 2023: -17.35%

Price change 2023 → 2024: 32.94%

Price change 2024 → 2025: 5.33%

Price change 2025 → 2026: -5.73%

Price change 2026 (year to date): -7.24%

Financial growth

Revenue CAGR (8 years): 11.70%

Earnings CAGR (8 years): 20.85%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.13

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 19.69

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 10.32% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

Create a free account Log in
02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
ResMed Inc.23.50.14+10.8 %🔒
Sartorius Stedim Biotech S.A.47.50.64+13.7 %–
Moderna, Inc.–0.22+37.8 %–
EssilorLuxottica S.A.33.60.37+14.2 %–
Sanofi8.80.28+2.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

Create a free account Log in
04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

Create a free account Log in
05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

Create a free account Log in
06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

Create a free account Log in
+

Key reported figures

Revenue, net income and net margin reported by ResMed Inc. over the latest fiscal years.

Revenue
5.7 bn USD
fiscal year 2026
Net income
1.5 bn USD
fiscal year 2026
Net margin
26.9 %
fiscal year 2026
Average annual growth
+12.1 %
Revenue growth over 5 years
Average annual growth
+11.9 %
Revenue growth over 10 years
Market cap
32.3 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20213.2 bn475 m14.8 %n/a
20223.6 bn779 m21.8 %+11.9 %
20234.2 bn898 m21.2 %+18.0 %
20244.7 bn1.0 bn21.8 %+10.9 %
20255.1 bn1.4 bn27.2 %+9.8 %
20265.7 bn1.5 bn26.9 %+9.9 %

Amounts converted to USD. Source: published annual accounts, collected on 30/10/2026.

+

Accounts and financial health

Balance sheet and cash flow published by ResMed Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
solid accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
11.69
safe zone (above 2.99)
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
360.01 USD
DCF above share price · share price 229.94 USD, gap +56.6 %
Net Debt / EBITDA
-0.18 x
net cash
Fiscal year20222023202420252026
Cash and investments274 m228 m238 m1.2 bn1.5 bn
Total Debt918 m1.6 bn874 m852 m826 m
Net Debt644 m1.4 bn636 m-358 m-643 m
Equity3.4 bn4.1 bn4.9 bn6.0 bn6.6 bn
Total assets5.1 bn6.8 bn6.9 bn8.2 bn9.0 bn
Operating cash flow351 m693 m1.4 bn1.8 bn1.8 bn
Investments (capex)156 m134 m99.5 m89.9 m156 m
Free cash-flow195 m559 m1.3 bn1.7 bn1.6 bn
Share buybacks00150 m300 m700 m
Dividends paid245 m258 m282 m311 m350 m

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)20.92 x
Price / book value5.53 x
Return on Equity (ROE)25.1 %
Return on Invested Capital (ROIC)21.2 %
Net margin27.8 %
Debt / equity0.10 x
Current ratio2.65 x
Interest coverage75.81 x
Free cash-flow yield8.8 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 05/11/2026.

+

Valuation and competitors

ResMed Inc. compared with its sector on the same exchange and with its main competitors.

Company P/E
21.4
21.5 % below the sector
Sector median P/E
27.2
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 02/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering ResMed Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
hold
35 analysts
Average price target
246.89 USD
from 213.00 USD to 300.00 USD, 27 targets over 12 months
Gap with the share price
+7.4 %
price 229.94 USD on 30/10/2026

Breakdown of ratings

strong buy 0buy 14hold 16sell 5strong sell 0

Analysts' average target 246.89 USD, DCF value 360.01 USD, share price 229.94 USD.

Average target over the last 3 months: 248.14 USD (7 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
20265.6 bn1.6 bn11.13 (11.08 / 11.23)20.78
20275.8 bn1.8 bn12.12 (12.04 / 12.23)19.014
20286.2 bn1.9 bn13.27 (12.97 / 13.81)17.314

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 11 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
30/10/2026CitigroupNeutralNeutral
30/10/2026KeybancOverweightOverweight
30/10/2026Wells FargoEqual WeightEqual Weight
30/10/2026RBC CapitalOutperformOutperform
15/09/2026RBC CapitalSector PerformOutperform

Source: ratings and forecasts published by analysts, collected on 03/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

ResMed Inc.: dividend history, last distributions, stock splits and earnings releases.

Frequency
quarterly
Last dividend
0.660 USD
ex-dividend on 12/11/2026
Last 12 months
2.46 USD
number of payments: 4
Yield
0.8 %
on the last known price
Years of increases
14
consecutive
Years of payments
14
uninterrupted

● Next ex-dividend date: 11/11/2026, 0.660 USD per share.

00.801.592.393.182012 : 0.340 USD20122013 : 0.840 USD2014 : 1.06 USD20142015 : 1.16 USD2016 : 1.26 USD20162017 : 1.36 USD2018 : 1.44 USD20182019 : 1.52 USD2020 : 1.56 USD20202021 : 1.62 USD2022 : 1.72 USD20222023 : 1.84 USD2024 : 2.02 USD20242025 : 2.26 USD2026 : 3.18 USD2026

Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
12/11/20260.660 USD17/12/2026
11/11/20260.660 USD17/12/2026
20/08/20260.660 USD24/09/2026
14/05/20260.600 USD18/06/2026
12/02/20260.600 USD19/03/2026
13/11/20250.600 USD18/12/2025
14/08/20250.600 USD18/09/2025
08/05/20250.530 USD12/06/2025

Earnings releases

DatePublished EPSExpected EPSSurprise
29/10/20262.912.69+8.2 %
06/08/20262.952.89+2.1 %
30/04/20262.862.80+2.1 %
29/01/20262.812.74+2.6 %
30/10/20252.552.51+1.6 %
31/07/20252.552.46+3.7 %

Stock splits

DateOperation
31/08/2010split: 2 shares for 1
03/10/2005split: 2 shares for 1
03/04/2000split: 2 shares for 1
17/11/1998split: 2 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in ResMed Inc.

Large funds tracked
25
hold the stock as of 2026Q2
Executives (insiders)
0 / 6
0 purchases, 6 sales in 130 days
US elected officials
5
4 purchases, 1 sales in 12 months

Indices: S&P 500 (since 26/07/2017).

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group18.9 m4.5 bn0.1 %-0.8 %2025Q4
State Street13.4 m2.6 bn0.0 %+101.1 %2026Q2
BlackRock12.3 m2.4 bn0.0 %+1.8 %2026Q2
Geode Capital Management4.4 m845 m0.1 %-0.0 %2026Q2
Invesco2.1 m402 m0.0 %+5.5 %2026Q2
Morgan Stanley1.9 m376 m0.0 %-28.2 %2026Q2
Northern Trust1.7 m331 m0.0 %-1.7 %2026Q2
Goldman Sachs1.2 m226 m0.0 %+15.6 %2026Q2

Latest insider transactions

DatePersonSideAmount
23/10/2026Rider Michael Jsale102,000 USD
07/10/2026Farrell Michael J.sale1.1 m USD
08/09/2026Farrell Michael J.sale1.1 m USD
02/09/2026Farrell Peter Csale227,688 USD
07/08/2026Farrell Michael J.sale1.0 m USD
05/08/2026Farrell Peter Csale1.8 m USD

Elected officials' disclosures

DateOfficialSideAmount
11/09/2026Ro Khannapurchase$1,001 - $15,000
27/03/2026Alan Armstrongpurchase$1,001 - $15,000
01/05/2026Ro Khannapurchase$1,001 - $15,000
13/04/2026Ro Khannapurchase$1,001 - $15,000
29/01/2026Ro Khannasale$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 05/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 02/06/1995
ISIN code
US7611521078
Workforce
9,980
full-time employees
Chief executive
Michael J. Farrell BE, MBA, SM
Next earnings
28/01/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about ResMed Inc.

What is the ResMed Inc. share price?

Latest recorded price: 229.94 USD on 30/10/2026, for a market cap of 32.3 bn USD.

What is the revenue of ResMed Inc.?

5.7 bn USD for fiscal year 2026, with net income of 1.5 bn USD (net margin 26.9 %).

Does ResMed Inc. pay a dividend?

Yes. Latest dividend: 0.660 USD per share, ex-dividend on 12/11/2026. Over 12 months: 2.46 USD. Yield on the latest known price: 0.8 %.

When does ResMed Inc. report its next earnings?

The next release is expected on 28/01/2027. EPS expected by analysts: 3.02.

What do analysts say about ResMed Inc.?

Out of 35 analysts: 14 buy or strong buy, 16 hold, 5 sell or strong sell. Average price target: 246.89 USD, i.e. +7.4 % from the share price.

What is the P/E ratio of ResMed Inc.?

Trailing 12-month P/E of 21.4, against 27.2 for the sector median on the same exchange (10-year median: 22.3).

Is ResMed Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US7611521078).

How many employees does ResMed Inc. have?

9,980 full-time employees according to the latest published profile.

Who runs ResMed Inc.?

Michael J. Farrell BE, MBA, SM is the company's chief executive.

Which large funds own ResMed Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, State Street, BlackRock, Geode Capital Management, Invesco.

07

Similar stocks